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ABSTRACT 
 
ERIC JOHN FORMEISTER: Comparative analysis of epigenetic and gene expression 
endpoints between tumorous and non-tumorous tissues from HCV-positive patients with 
hepatocellular carcinoma 
(Under the direction of Ivan I. Rusyn) 
 
 
Transcriptional silencing induced by promoter CpG island hypermethylation is an 
important epigenetic mechanism of hepatocarcinogenesis. The goals of our study were to 
examine promoter methylation and mRNA levels of candidate genes, as well as global 
changes in DNA methylation, in a cohort of HCV-positive HCC patients from Japan. 
Methylation-specific PCR was used to assess the methylation status of seven cancer-related 
genes, while the methylation status of long interspersed nuclear elements was used as marker 
of global genomic methylation, in tissues obtained from patients who underwent tumor 
resection surgery. Methylation frequencies for most of the genes were significantly higher in 
tumorous versus non-tumorous tissues. The methylation status of only three genes correlated 
with reduced mRNA levels. Genomic DNA was significantly more hypomethylated in 
tumorous tissues, and was associated with shorter recurrence but not with clinicopathological 
variables. In summary, this study establishes an aberrant gene-specific and global 
methylation profile in HCV-associated HCCs.  
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CHAPTER 1 
 
HEPTATOCELLULAR CARCINOMA BACKGROUND AND LITERATURE REVIEW 
 
 
Epidemiology, Risk Factors, and Pathogenesis 
 
Hepatocellular carcinoma (HCC) is the fifth most common human neoplasm and the 
third most fatal worldwide (1). Over 80% of HCC cases are attributable to three principal 
etiological factors: chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) 
and aflatoxin B1 (AFB1) exposure (2).  There is profound geographic variation in both HCC 
incidence and the background liver disease, with the highest density of cases occurring in 
Southeast Asia due to chronic HBV infection (as in China) or HCV infection (as in Japan) 
(3).  Despite decreasing incidence trends for many major human cancers, HCC incidence has 
actually risen over the last three decades in several countries, including the U.S. and Japan, 
due to increasing prevalence of HCV infection (4 – 6).  In Japan, HCV infection is the major 
cause of HCC and is implicated in over 70% of all HCC cases (4).  Because the molecular 
pathogenesis of HCC is specific to the underlying liver pathology, experimental 
investigations of distinct HCC sub-types are needed in order to elucidate the etiology-specific 
genetic and epigenetic changes that facilitate liver tumorigenesis. Thus, the following thesis 
details the epigenetic investigations of tissue samples from a homogeneous cohort of HCV-
positive, HBV-negative Japanese patients who underwent curative tumor resection surgery. 
The current multi-stage histopathologic model of HCV-associated 
hepatocarcinogenesis begins with chronic HCV infection, which persists in 80% of 
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individuals. After protracted infection with HCV, close to 30% will eventually develop liver 
cirrhosis, the predominant antecedent liver pathology in hepatocarcinogenesis. Virtually all 
(>97%) individuals who are chronically infected with HCV and develop HCC exhibit HCV-
induced cirrhosis, while the rest demonstrate advanced fibrosis and/or hepatitis (7).  Overall, 
then, HCC develops from the pathologic context of a persistent necroinflammatory hepatic 
disease (8).  Similar to other epithelial cancers, development of HCC has a prolonged 
induction period lasting 20 to 40 years that includes 10 to 30 years of preneoplastic lesions, 
followed by 5 to 10 years of developing dysplastic hepatocytes and nodules before clinical 
detection of HCC (2). 
Despite the well-defined histologic progression from normal liver to HCC, the 
molecular pathogenesis of HCV-associated HCC is largely unknown (8).  Recent studies, 
however, have provided strong molecular evidence for the role of inflammation-mediated 
increases in oxidative stress and increased risk of tumor formation. Intractable HCV infection 
elicits a chronic inflammatory response characterized by overproduction of reactive oxygen 
species (ROS) (9).  High ROS levels overpower the liver’s mechanisms for anti-oxidant 
scavenging, and are either directly cytotoxic or increase the rate of oxidative DNA damage, 
including the formation of highly mutagenic 8-hydroxy-deoxyguanosine DNA lesion. 
Furthermore, it has been shown in a mouse model of HCV-associated carcinogenesis that 
HCV infection can directly increase the production of ROS, independently of a state of 
chronic inflammation (10). 
A number of dysregulated molecular signaling pathways have been implicated in 
HCC tumorigenesis, for instance,  activation of the Wnt/β-catenin pathway and inactivation 
of E-cadherin (9).  Interestingly, the core proteins encoded in the HCV genome have been 
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shown to directly interact with and mediate activity of several of the cyclin/cyclin-dependent 
kinase cell cycle control proteins  (11). Thus, the landscape of molecular alterations in HCV-
associated hepatocarcinogenesis is beginning to emerge, but is far from complete. 
Additionally, the contribution of epigenetic changes to the aberrant molecular milieu in 
preneoplastic and neoplastic liver tissue is incompletely characterized. 
 
Clinical Management and Tumor Recurrence  
 
Clinical management of HCC is particularly challenging due to the lack of predictive, 
diagnostic or prognostic biomarkers and because HCC is often refractory to chemotherapy 
and radiation treatment  (12). Common therapies in early-stage HCC include tumor resection, 
liver transplantation, and targeted ablation by radiofrequency or ethanol injection (13). 
Tumor resection is the most widely applicable curative treatment option (14); however, 
prognosis following tumor resection is poor, with a 5-year survival as low as 35% (12).  
A major contributor to the dismal prognosis following tumor resection is the high 5-
year HCC recurrence rate (75% to 100%) (14).  Additional tumors in the liver remnant can 
develop from either intrahepatic metastasis from the primary tumor or multicentric 
occurrence (14). The latter suggests that genetically and epigenetically distinct tumors can 
arise independently from the same diseased background liver, a theory first described 
histopathologically by Slaughter et al. in 1953 as “field cancerization.” This concept posited 
that additional tumors arise from histopathologically and biologically altered patches of 
preneoplastic tissues, and can at least partially account for the high rate of recurrence in some 
cancers (15).  From a genetic perspective, field cancerization has been demonstrated in 
several cancers, including those of the head and neck, lung, skin, breast, colon and bladder 
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(16).  Propagation of genetic mutations acquired by a stem cell produce clonal patches of 
genetically altered cells, which develop into larger fields of genetically compromised cells. 
Additional mutations and eventual clonal divergence can lead to multiple primary tumors 
from the same field (16). Despite the obvious clinical implications of field cancerization for 
risk of HCC recurrence, field cancerization has not been fully characterized in hepatocellular 
carcinoma, nor has field cancerization been examined through an epigenetic lens. And 
finally, though the underlying assumption in field cancerization is that tumor recurrences 
represent additional monoclonal tumors (a so-called “second primary tumor”), the literature 
regarding tumor clonality (e.g., monoclonal versus polyclonal) has not been consistent 
Though clinicopathological features, such as tumor size, number, and differentiation, 
are useful in identifying patients who are at-risk for recurrence, these characteristics are 
seldom able to prospectively predict recurrence-free survival, partially because HCC is being 
diagnosed at increasingly earlier stages (17). Thus, the search for better, non-invasive, 
predictive biomarkers remains a high clinical priority. 
 
Gene Expression, Epigenetics and Biomarkers 
 
Because HCC is a cancer of heterogeneous etiologies, intensive research has focused 
on the applicability of gene expression profiles for molecular sub-typing of HCC cases. 
Several groups have used whole genome microarrays and a transcriptomic approach for 
identifying specific molecular classes of HCC (18 – 19).  Furthermore, several investigators, 
including those from our laboratory, have succeeded in establishing predictive recurrence-
free survival signatures based on gene expression in tumorous and non-tumorous tissues from 
patients undergoing curative resection, demonstrating the prognostic utility of molecular 
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biomarkers in investigations of HCC recurrence. However, the clinical adaptability of gene 
expression studies of recurrence-free survival are limited in that the process requires tissue 
biopsies, is resource-, time-, and data-intensive, and gene expression changes are typically 
quite unstable and dynamic characteristics of diseased tissues. 
Due to the above limitations and the continued paucity of strong, independent 
predictors of recurrence-free survival, very recently, investigations into the epigenetic 
changes occurring during hepatocarcinogenesis have become a focus of HCC research. In 
contrast to genetic changes, which largely refer to alterations in the actual sequence of DNA, 
epigenetics refers to heritable changes in gene expression that do not involve changes in the 
DNA sequence  (20). A well-investigated epigenetic mechanism affecting gene expression is 
the addition of methyl residues to cytosine nucleotides that are 5’ to guanosine nucleotides in 
the DNA sequence (called CpG dinucleotides). CpG islands are short stretches of DNA 500 
to 4,000 bp in length that are rich in CpG sequences and are found in the promoter region and 
first exon of more than half of all genes in the mammalian genome (21).  In normal 
mammalian cells, CpG islands are typically unmethylated. (20).  
In cancer cells, however, promoter hypermethylation results in transcriptional 
repression of critical tumor suppressor and other cancer-related genes and is important 
epigenetic event in both the initiation and progression phases of carcinogenesis (21), 
including hepatocarcinogenesis   (22 – 23).  The observation that a myriad of tumor 
suppressor genes are aberrantly methylated in cancer has led to the characterization of some 
tumors as demonstrating a CpG island methylator phenotype (CIMP), a phenotype which 
identifies neoplasms with a high degree of epigenetic instability (24).  Additionally, in liver 
and other cancers, gene-specific promoter hypermethylation is often accompanied by global 
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genomic hypomethylation, an epigenetic event that can lead to oncogene activation and 
overall genomic instability, further disposing preneoplastic tissues to malignant 
transformation (25).   
Several groups have focused on  establishing profiles of aberrant DNA methylation in 
both the tumorous and non-tumorous tissue from the surgical margin in order to characterize 
epigenetically regulated genes that are important in hepatocarcinogenesis and might serve as 
useful clinical biomarkers. Among the most frequently cited cancer-related genes found to be 
hypermethylated in tumorous tissues are P16INK4A, RASSF1A, SOCS-1, GSTP1, APC, RIZ1, 
and MGMT (22; 26 – 31).  Methylation profiling of HCC tissues has largely followed a 
paradigm of trying to map the progressive accumulation of aberrant methylation of specific 
tumor suppressor genes throughout the histopathologic steps of hepatocarcinogenesis (22; 32 
– 33).   Apart from cementing the notion that cancer is a multi-hit genetic and epigenetic 
disease, these studies have been crucially important in providing evidence for field 
cancerization of HCC, specifically, high frequencies of methylation in the surrounding non-
neoplastic tissue.  
Others have tested the potential utility of using methylation status as a predictor of 
either overall or recurrence-free survival after resection, and found that methylation of 
GSTP1, CDH1, P16INK4A, CRABP1, and SYK in tumorous tissues corresponds to shortened 
overall survival (22; 34 – 35), while specific promoter hypermethylation of MGMT in 
tumorous tissues and RIZ1 in the non-tumorous surgical margin are significantly associated 
with recurrence-free survival (29).  In addition to findings that gene-specific methylation 
status is associated with recurrence-free survival, several investigators have demonstrated 
that global DNA hypomethylation in tumorous tissues is significantly inversely correlated 
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with overall patient survival (25; 36).  Finally, the recent finding that aberrant methylation is 
detectable in serum DNA in patients several years before clinical diagnosis of HCC (37) 
offers the exciting potential for the clinical application of non-invasive methylation analysis 
for predict HCC cases or prognosticating recurrence-free survival after tumor resection. 
 
Scope of the Thesis and Outline of Findings 
 
Almost all of the aforementioned epigenetic studies of HCC consisted of patients who 
were heterogeneous with respect to the underlying disease etiology, and thus somewhat 
hinder the capacity to delineate the epigenetic aspects of specific HCC sub-types. Thus, 
characterization of epigenetic changes specific to disease etiology and identification of genes 
whose promoter methylation status might be predictive of recurrence-free survival are still 
important clinical goals. The research detailed herein consisted of a well-defined cohort of 
HCV-positive, HBV-negative Japanese HCC patients who underwent curative tumor 
resection surgery and who were followed thereafter to determine the time to tumor 
recurrence. This report describes both differential hypermethylation of seven cancer-related 
genes and differential global genomic hypomethylation between tumorous and adjacent non-
tumorous tissues. I have identified associations between the methylation status of several 
tumor suppressor genes and clinicopathological features and show that methylation of RIZ1 
in non-tumorous tissues is a significant predictor of earlier tumor recurrence. Additionally, I 
demonstrate that the level of global genomic hypomethylation in tumorous tissues is 
significantly higher in patients with shorter versus longer recurrence-free survival times, and 
that the level of hypomethylation in non-tumorous tissues from all patients is associated with 
the time to recurrence. Comparative analyses between the methylation status of the cancer-
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related genes and corresponding gene expression data are shown. Finally, I describe efforts to 
use a predictive recurrence-free survival gene expression signature, derived from the same 
patients, to guide the search for new genes that are potentially regulated by promoter 
hypermethylation during carcinogenesis. Overall, it is clear that epigenetic changes in both 
tumorous and non-tumorous tissue from the surgical margin can yield prognosis-related 
information and can supplement and enhance typical clinicopathological data. Clinically, 
examination of the epigenetic changes in both the resected tumor and the liver remnant can 
provide important complementary information to be used in post-operative management.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
Patient Population and Sample Collection 
 
The patient cohort consisted of 49 HCV-positive, HBV-negative patients with 
primary HCCs who underwent curative resection surgery at the University of Yamanashi 
Hospital (Yamanashi Prefecture, Japan) between 2000 and 2007 (mean age = 66.2±8.1 years; 
37 males and 12 females). The viral hepatitis status was determined by one or more of the 
following techniques: (i) presence of anti-HCV and anti-HBV reactive serum proteins; (ii) 
reverse transcription-PCR for serum HCV-RNA; or (iii) branched DNA-HCV probe assay.  
After surgery, patients returned each month to the ambulatory care clinic for follow-up tests, 
including measurement of α-fetoprotein levels. Ultrasounds or computed tomography scans 
of the liver were performed every 3 or 6 months, respectively, to determine the time of 
recurrence. Follow-up data was collected until a detectable recurrence, patient death, or the 
end of the study period (July, 2008). Informed consent was obtained in accordance with the 
Institutional Board on Ethics for Human Science at the University of Yamanashi.  
Following removal of the tumor(s), fresh tissue samples were collected from the 
tumorous and the non-tumorous surgical margin, frozen in liquid nitrogen and stored at -80º 
C until laboratory processing. Due to insufficient tissue quantities from several of the 
patients, 43 tumorous and 45 non-tumorous tissue samples were used in the present study, 
representing 39 paired tissue samples from the same patients. DNA from non-transplant 
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grade human livers (free from liver disease according to the pathology reports) was kindly 
provided by Drs. Stephen Ferguson and Jonathan Jackson (LifeTechnologies/CellzDirect, 
Durham, NC) and used as controls. Figure 1 offers an overview of the experimental setup. 
 
 
 
 
DNA isolation and sodium bisulfite conversion 
 
 DNA was isolated from frozen tissue samples by a procedure that was slightly 
modified from one reported previously (38).  Briefly, ~100 mg tissue was thawed and 
suspended in 1 mL 1X PBS (Sigma, St. Louis, MO), then mechanically homogenized with a 
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Retsch Tissue Lyser (Qiagen, Valencia, CA). The homogenate was centrifuged at 1,700 x g 
for 5 minutes to pellet the nuclei. The nuclei were re-suspended and digested in 1 mL Cell 
Lysis Solution (5 Prime Inc., Gaithersburg, MD) and 25 µL Proteinase K (Roche 
Diagnostics, Indianapolis, IN) overnight at 4º C on an orbital shaker. Protein was precipitated 
using 330 µL protein precipitation solution (5 Prime Inc., Gaithersburg, MD) and 
centrifugation at 2,000 x g for 10 minutes. DNA/RNA was precipitated from the supernatant 
using 100% isopropanol, washed with 70% ethanol, then re-suspended in 1 mL Cell Lysis 
Solution for 2 hours at 4º C on an orbital shaker. Following RNA digestion with 4.5 µL 
Ribonuclease A (Sigma, St. Louis, MO) at 37º C for 30 minutes, the above protocol for 
protein precipitation and DNA precipitation and washing was repeated. DNA was re-
suspended in 150 µL ddH2O and stored at -80º C until use. 
In order to determine the specific promoter methylation status of several cancer-
related genes in tumorous, non-tumorous, and control liver samples, isolated DNA was 
subjected to a protocol that uses sodium bisulfite treatment to chemically convert 
unmethylated cytosine residues to uracil, while methylated cytosines (5-methylcytosine) 
remain unchanged (38).  This allows the design of two different primer sets, one which will 
specifically amplify methylated DNA and one which will specifically amplify unmethylated 
DNA.  In these experiments, a commercially available kit for rapid sodium bisulfite 
conversion was used (EZ DNA Methylation-Gold Kit, Zymo Research, Orange, CA). For 
bisulfite conversion, 2 µg of isolated genomic DNA  was used following the manufacturer’s 
suggested protocol. 
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Methylation-specific Polymerase Chain Reaction (MSP) 
 
 Methylation-specific polymerase chain reaction (MSP) takes advantage of the 
chemical conversion of unmethylated cytosine residues to uracil following sodium bisulfite 
treatment (39) and the selective amplification by the methylated or unmethylated primers. 
Each bisulfite-treated DNA sample was run in two reactions; one with a methylated primer 
set and one with an unmethylated primer set. The methylated and unmethylated primer 
sequences for each of the seven cancer-related genes were taken from previously published 
reports. The sequences, amplicon product sizes and associated references for P16INK4A, 
SOCS-1, RASSF1A, APC, GSTP1, RIZ1 and MGMT are shown in Table 1.  
 
 
 
 
  13 
Briefly, 50 ng of bisulfite-converted DNA (10 µL), 50 pmol forward and reverse 
primers (5 µL each, Nucleic Acids Core Facility, UNC-Chapel Hill), 5 µL ddH2O, and 25 µL 
2X Amplitaq Gold PCR Master Mix (Applied Biosystems, Foster City, CA), for a final 
reaction volume of 50 µL, were subjected to MSP under the following conditions: 95º C for 
10 minutes, 35 cycles of 45 seconds at 95º C, 60 seconds at the annealing temperature 
specific for each primer set, 60 seconds at 72º C, and a final 10 minute extension at 72º C. 
The final PCR products were vacuum-concentrated to 20 µL and run on a 1.75% agarose gel. 
Ethidium bromide stain and Kodak ID Imager/Image Analysis Software (Sigma, St. Louis, 
MO) were used for DNA visualization and image processing. The presence of a band at the 
expected fragment length was scored as positive for methylation; absence was scored as 
negative. Figure 2 shows a representative MSP gel image of RIZ1, with all of the tumorous 
DNA methylated and most of the non-tumorous DNA unmethylated. 
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Combined Bisulfite Restriction Analysis (COBRA) of LINE-1  
There are about half a million long interspersed nuclear elements (LINE) in the 
human genome and DNA methylation occurs mainly in these repetitive elements. Thus, 
examining LINE-1 methylation is a suitable proxy for evaluating global genomic methylation 
(40).  To assess the level of global genomic methylation, a 413 bp region of LINE-1 was 
amplified via MSP as previously described (40).  The product was aliquoted into two 
samples; half was digested with HinfI restriction endonuclease (New England Biolabs, 
Ipswich, MA) and half was left undigested. Each treatment was run in tandem on a 1.75% 
agarose gel and visualized as detailed above. Because Hinf1 will only digest repetitive 
elements that were originally methylated, the relative level of hypomethylation can be 
quantified using densitometry of the band intensities with the aforementioned imager and 
image software. Specifically, a higher ratio of the digested to undigested 413 bp band 
intensity indicates that less of the DNA from that sample is methylated, that is, DNA is more 
globally hypomethylated in that tissue sample. Figure 3 shows a representative gel image 
used to quantitate relative band intensities, with more of the non-tumorous DNA originally 
methylated than the tumorous DNA. 
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Gene Expression Data 
 
 As part of a companion study conducted by other members of the Rusyn Laboratory 
(Tsuchiya et al., Mol Cancer, 2010 (in press)), gene expression data from microarrays were 
available for most of the tumorous (41/43) and non-tumorous (43/45) samples. Raw 
microarray data was archived in Gene Expression Omnibus (GSE17856) and is available to 
the public. Levels of mRNA were compared to methylation status of the seven genes 
investigated and analyses were performed to determine the relationship between gene 
expression, recurrence-free survival and clinicopathological variables.  
Gene expression data was further used to guide the search of new candidate genes 
that are potentially regulated by promoter hypermethylation. The submitted study referenced 
above (Tsuchiya et al., Mol Cancer, 2010 (in press)) established a predictive recurrence-free 
survival signature based on gene expression of 91 genes in the non-tumorous tissue samples 
from patients with a late (>1 year) recurrence. Cox scores for the association between gene 
expression and recurrence-free survival were obtained for all genes. The ten genes with the 
largest positive Cox scores (associated with earlier recurrence) and the ten genes with the 
largest negative Cox scores (associated with later recurrence) were selected. A 2,000 
nucleotide sequence of DNA obtained from the Genome Browser at the University of 
California, Santa Cruz (http://genome.ucsc.edu/), including 1000 bp upstream and 1000 bp 
downstream of the transcriptional start site, was analyzed for the presence of potential CpG 
islands using Methyl Primer Express Software (Version 1.0, Applied Biosystems, Foster 
City, CA). Unmethylated and methylated primer sets were designed using the software for 
those genes for which putative promoter CpG islands were detected and synthesized at the 
UNC Nucleic Acids Core Facility (Chapel Hill, NC). To screen for aberrant promoter 
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methylation of these genes, methylation status of each gene was determined using MSP on 
DNA from 8 paired tumorous and non-tumorous tissues, including 4 pairs from patients with 
an early (<2 years) recurrence and 4 pairs from patients with a late (>2 years) recurrence.  
 
Statistical Analyses 
 
 Most of the statistical tests were performed separately within both the tumorous and 
non-tumorous sample cohorts. McNemar’s, chi-square, Fisher’s exact tests and both paired 
and unpaired Student’s t-test were used to compare methylation frequencies between 
tumorous and non-tumorous samples, to determine associations between methylation status 
of each gene and clinicopathological variables, to examine differences in gene expression 
according to methylation status, and to compare LINE-1 methylation between tumorous and 
non-tumorous samples. Univariate and multivariate Cox proportional hazard models were 
used to investigate relationships between promoter methylation status, gene expression, and 
clinicopathological data with recurrence-free survival with JMP software (version 6, SAS 
Institute Inc., Cary, NC). Kaplan-Meier curves were generated and Mantel-Cox log-rank tests 
were performed to analyze the association between recurrence-free survival and gene-
specific or global methylation status using software from GraphPad Prism (version 5, San 
Diego, CA). A p-value <0.05 was considered statistically significant. Gene expression values 
(log2 transformed ratios of expression between the test sample and a universal reference) 
were visualized using Cluster and TreeView algorithms (41). 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
CHAPTER 3 
 
RESULTS 
 
 
Clinicopathological Characteristics of the Patient Population 
 
 In all of the statistical analyses performed in this study, the full patient cohort (49 
subjects) was divided into patients for which DNA and gene expression data from HCC 
samples (n=43), or non-tumorous samples (n=45) were available. There were 39 paired 
tumorous and non-tumorous samples from the same patient. The patients in each sub-cohort 
did not differ significantly with respect to any of the clinicopathological variables (data not 
shown). As a first step to consider the relationship between the typical clinicopathological 
variables of HCC resection patients, including demographic characteristics, tumor 
information, laboratory results, and the recurrence-free survival, univariate Cox proportional 
hazards analyses were performed. In both sub-cohorts, tumor number, tumor diameter, and 
tumor stage were significantly associated with an earlier recurrence according to Log-Rank 
tests (Table 2).   
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Gene-specific Promoter Methylation Analysis in Tumorous and Non-tumorous Tissues 
 
 Aberrant promoter methylation of P16INK4A, SOCS-1, RASSF1A, APC, GSTP1, RIZ1, 
and MGMT is commonly reported in epigenetic studies of HCC. Here, I examined the 
methylation profile of these 7 genes, which are associated with a number of dysregulated 
pathways during carcinogenesis, in both tumorous and non-tumorous samples from HCV-
positive HCC patients (Table 3). All of the genes were almost entirely unmethylated in the 
DNA from control human livers.  The frequencies of methylation of all genes, except 
MGMT, were significantly higher (p<0.05, Fisher’s exact test) in tumorous samples as 
compared to control liver. In non-tumorous samples, the methylation frequencies of only 
SOCS-1 and RASSF1A were significantly higher than those in controls.  
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 I applied McNemar’s version of the chi-square test to compare the methylation 
frequency between the 39 pairs of tumorous and non-tumorous tissue samples. The 
frequencies of methylation of P16INK4A, RASSF1A, APC, GSTP1, and RIZ1 were significantly 
higher in tumorous as compared to non-tumorous tissues, while the methylation frequency of 
MGMT showed an opposite trend, and SOCS-1 exhibited equally high methylation 
frequencies between the sub-cohorts (Table 3).  
 
 
 
 In addition to identifying differences in the degree of methylation between tumorous 
and non-tumorous tissues, I was interested in exploring the CpG island methylator phenotype 
in HCCs. Figure 4 shows the distribution of the number of samples with the specified number 
of methylated genes in control, non-tumorous and tumorous tissues. There was a statistically 
significant increase in the number of methylated genes as pathology progressed from normal 
to neoplastic; the average number of methylated genes (± SD) in control, non-tumorous, and 
tumorous samples was 0.1 (±0.3), 2.2 (±1.0), and 4.9 (±1.0), respectively (p<0.001, unpaired 
t-tests). Though it was clear that there is a high degree of methylation in cancer-related genes 
from non-tumorous tissues of the surgical margin, the significant upward shift in the number 
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of methylated genes in the tumorous tissues suggests involvement of the CpG island 
methylator phenotype in HCV-associated liver tumors (Figure 4). 
 
 
 
 
 The nonzero number of non-tumorous samples for which promoter methylation was 
detected in each gene examined, and the significantly higher methylation of SOCS-1 and 
RASSF1A relative to control liver, provide evidence for epigenetic field cancerization (29; 
41) within the preneoplastic tissue adjacent to HCC. To further explore this concept, and to 
investigate the tumor clonality in our tissue samples, we assessed the accordance between 
methylation status in tumorous and non-tumorous tissue from the same patient for each gene. 
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Nomoto et al. (43) suggested that to characterize a tumor as monoclonal or polyclonal in 
origin, a comparison of the methylation status between paired tumorous and non-tumorous 
samples might be performed. There are four possible combinations of methylation status for 
each tissue pair: the gene is methylated in both the non-tumorous tissue and the 
corresponding tumorous tissue (T+/NT+), the gene is methylated in the tumorous, but not in 
non-tumorous tissue (T+/NT-), the gene is methylated in neither tissue (T-/NT-), or the gene 
is methylated in the non-tumorous, but not the tumorous tissue (T-/NT+). The first three 
combinations can be identified as accordant and have been suggested to be of monoclonal 
origin (29). The presumption is that the tumorous tissue represents the most highly 
genetically and epigenetically aberrant; thus, all three of the aforementioned combinations 
show the degree of epigenetic alterations in the tumorous tissues is either the same or greater 
than in the non-tumorous tissues. However, if the pre-cancerous tissue from the surgical 
margin is methylated but the tumorous tissue is not (the fourth combination), this 
“discordant” status suggests that the tumor has arisen from a polyclonal origin, because the 
field is epigenetically altered in such a way that has not been preserved in the tumorous 
tissue. However, this analysis does not permit definitive conclusions regarding whether or 
not the tumor is monoclonal; rather, it only allows one to characterize the tumor as 
potentially polyclonally-derived or not. When comparing each sample pair type by each 
specific gene (Table 4), the majority of tissues were either T+/NT- (avg. 42%) or T+/NT+ 
(avg. 28%) (Figure 5B). However, at least one sample pair was discordant (that is, T-/NT+) 
for methylation in all genes except RASSF1A and APC, indicating that these tumors were 
polyclonally derived and providing support for multicentric HCC tumorigenesis, as described 
by others (17).  
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Additionally, we analyzed accordance between the methylation status in tumorous 
and corresponding non-tumorous tissues for all 7 genes and found that 72% of the pairs were 
accordant for all genes. Of the 11 cases that were not accordant for all genes, 10 were 
discordant for only one gene, while one was discordant for two genes  (Figure 5A). This 
variable clonality in HCV-associated HCC underscores the complex molecular etiology of 
hepatocarcinogenesis.   
The different tumor clonalities suggested by the accordance analysis prompted us to 
examine whether or not the recurrence-free survival time differed between accordant and 
discordant cases. Though discordant cases (the potentially polyclonally derived tumors) had a 
longer average time to recurrence (29.3 months) versus the accordant cases (20.9 months), 
this difference was not significant (p = 0.20, data not shown). We speculate that perhaps 
tumors derived from polyclonal preneoplastic tissue require more time to acquire the 
necessary epigenetic aberrations to manifest as a tumorous mass. This finding, however, is 
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consistent with the notion that later tumor recurrences represent multicentric, de novo tumor 
formation, while earlier recurrences are thought to arise from monoclonal intrahepatic 
recurrences (14). 
 
 
 
 
Association Between Promoter Methylation Status, Recurrence-free Survival, and 
Clinicopathological Variables 
 
To investigate the association between methylation status of the genes and 
recurrence-free survival, we performed univariate Cox proportional hazards analyses for all 
genes in both the tumorous and non-tumorous cohorts. We observed that hypermethylation of 
RIZ1 in non-tumorous tissues was the only gene significantly associated with a higher risk 
for earlier recurrence (HR=2.29; 95% CI=1.22–3.83; p=0.01, Table 3). However, this 
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relationship was not significant in multivariate analysis when other significant univariate 
clinicopathological predictors (tumor diameter, tumor number, and tumor stage) were 
included (data not shown). Figure 6 shows Kaplan-Meier survival curves according to the 
status of RIZ1 and P16INK4A (a representative non-significant gene) methylation in tumorous 
and non-tumorous tissues. 
 
 
 
 
In addition, we examined the relationship between gene methylation status and 
clinicopathological variables. Only a few significant (p<0.05) relationships were found, 
including an association between RIZ1 methylation and both age and tumor diameter in the 
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non-tumorous sub-cohort and an association between GSTP1 methylation and tumor stage in 
the non-tumorous cohort (Table 5). 
 
 
 
 
Global DNA Methylation Analysis in Tumorous and Non-tumorous Tissues 
 
 Though promoter hypermethylation of specific genes is a common epigenetic event in 
hepatocarcinogenesis, this specific aberration is often concurrent with global DNA 
hypomethylation (44).  Therefore, in addition to examining gene-specific hypermethylation, 
the level of global hypomethylation in tumorous and non-tumorous tissues was assessed by 
analyzing the level of LINE-1 methylation as a marker for global DNA methylation status. 
LINE-1 was significantly (p<0.001) more hypomethylated in tumorous tissues as compared 
to non-tumorous tissues (Figure 7A). When patients were divided into those with an earlier 
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recurrence (<1 year) or later recurrence (>1 year), the level of hypomethylation in the 
tumorous samples was significantly higher in patients with earlier recurrences. The same was 
true when assigning 2 years as the cutoff between early and late recurrence (Figure 7B). 
When patients were sub-divided into two groups based on the median value of LINE-1 
hypomethylation in non-tumorous tissues, a nearly significant difference in recurrence-free 
survival outcome between the groups was observed; patients with hypomethylation levels 
above the median value experienced earlier recurrences (p=0.06, Log-Rank test (Mantel-
Cox), Figure 7C).  However, this relationship did not exist according to hypomethylation 
levels in the tumorous tissues (p = 0.61, data not shown). And when treating LINE-1 
hypomethylation levels as a continuous variable, Univariate Cox proportional hazard analysis 
revealed that the level of global DNA hypomethylation in either tissue type was not 
significantly related to recurrence-free survival (p = 0.36, tumorous tissues; p = 0.26, non-
tumorous tissues, data not shown). The level of LINE-1 hypomethylation in tumorous tissues 
was also significantly inversely correlated with ALT levels (p=0.03, Table 6). In non-
tumorous tissues, LINE-1 hypomethylation was significantly directly correlated with tumor 
diameter (r2 = 0.11, p = 0.03, Table 6).  
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No other significant associations between LINE-1 hypomethylation levels and 
clinicopathological variables were observed. Of note, there was no association between the 
degree of LINE-1 hypomethylation and the methylation status of any of the 7 genes, or the 
number of genes methylated in either sub-cohort (Table 6). 
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Variable Concordance between Gene Expression and Promoter Methylation Status in 
Tumorous and Non-tumorous Tissues 
 
Though the functional consequence of promoter methylation is frequently presumed 
to be a reduction in gene expression, this relationship is seldom evaluated in clinical studies. 
Using microarray data collected from the same tumorous and non-tumorous samples, we 
were able to compare the promoter methylation status of the 7 candidate genes with their 
mRNA levels. There were significant differences in expression levels for 6 genes between 
tumorous and non-tumorous tissues (Figure 8). When tumorous and non-tumorous sub-
cohorts were analyzed together, corresponding gene expression levels were significantly 
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lower in samples with RIZ1 methylation (p<0.01) and GSTP1 methylation (p=0.01). 
Interestingly, P16INK4A expression was significantly higher in methylated versus 
unmethylated tissues, a relationship that was also true when analyzing only tumorous tissue.  
Expression of MGMT was also significantly lower in samples with MGMT methylation in the 
non-tumorous sub-cohort (Figure 8; Table 7). 
 
 
 
 
The univariate Cox proportional hazards model analyses for the association between 
gene expression and recurrence-free survival showed that only one probe for the SOCS-1 
gene was significant, and only in non-tumorous tissue (HR=8.09; 95% CI=1.11–52.5; 
p=0.04). For this same probe, gene expression in methylated tissues was marginally 
significantly lower (p=0.06) in pooled tumorous and non-tumorous tissues (Table 7). 
  30 
 
 
 
 
We previously reported a strongly predictive recurrence-free survival signature based 
on gene expression data of 91 genes in non-tumorous tissue from patients with a late (>1 
year) recurrence (Tsuchiya et al., Mol Cancer, 2010 (in press)). To examine whether 
differences in expression of these biomarker genes may be linked to promoter methylation, 
we chose the top 20 genes with the most significant Cox scores with regards to recurrence-
free survival for methylation analysis (Figure 9). Of these, 9 (45%) had CpG islands in the 
promoter region: SAFB, MKL1, TNKS1BP1, PPP2R5C, GATA4, RASD1, C1orf57, ACTR10, 
and CCDC126. Only promoter hypermethylation of GATA4 had been previously reported in 
HCC tissues (25); thus, eight of these genes represented novel genes for methylation 
analysis.  Methylated DNA- and unmethylated DNA-specific primers were designed. We 
screened 8 paired tumorous and non-tumorous samples (4 from patients with <1 year 
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recurrence and 4 from patients with >1 year recurrence) for CpG region methylation in these 
9 genes and found them to be uniformly unmethylated in both tissue types (data not shown).  
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
CHAPTER 4 
 
DISCUSSION 
 
 
Discussion of Results 
 
Gene-specific promoter hypermethylation and global DNA hypomethylation are 
common epigenetic aberrations found in human liver tumors; however, answers to questions 
regarding the epigenetic changes specific to the underlying disease etiology remain elusive. 
Additionally, though the functional consequence of promoter hypermethylation is 
transcriptional silencing of the associated gene, this assumption often goes untested, as few 
have concurrently investigated both methylation and gene expression. In this study, we 
examined both gene-specific changes in methylation and expression levels and global DNA 
hypomethylation in tumorous and non-tumorous surgical margin tissues, and investigated the 
relationship between epigenetic changes and clinicopathological variables, recurrence-free 
survival and altered gene expression. Herein, we report significant differences in both 
specific gene hypermethylation and global genomic hypomethylation between tumorous and 
non-tumorous tissues and confirm the utility of RIZ1 hypermethylation in non-tumorous 
tissues as a predictive biomarker of earlier recurrence following tumor resection. 
Our gene-specific methylation analyses examined genes selected based on their 
relevance in several cancer pathways (e.g., cell cycle regulation, inhibition of the Ras 
pathway, xenobiotic metabolism and DNA repair) and previous reports of hypermethylation 
in HCC (22;  26 – 31).  Consistent with other studies, we observed higher frequencies of 
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promoter methylation in tumorous versus non-tumorous tissues for P16INK4A, RASSF1A, 
APC, GSTP1, and RIZ1. The high frequency of methylation in tumorous tissues for all genes, 
except MGMT, as well as the high average number of genes methylated per sample (4.9), 
together suggest the presence of the CpG island methylator phenotype in HCV-associated 
HCC, a feature that characterizes many human neoplasms (24).  Interestingly, however, both 
SOCS-1 and RASSF1A were hypermethylated at high frequencies in non-tumorous tissues 
and MGMT was significantly more methylated in non-tumorous tissues. Indeed, all of the 
genes examined were methylated in at least two of the non-tumorous samples, and the 
average number of methylated genes in non-tumorous samples was 2.2, substantiating the 
notion posited by others that epigenetic field defects in surrounding non-neoplastic tissues 
are detectable events in HCC tumorigenesis (33; 43).  Others have demonstrated that 
promoter hypermethylation is far more frequent in non-tumorous HCV-positive liver from 
HCC patients as compared to non-tumorous HCV-negative liver (32), a finding that is 
recapitulated in the present study. Thus, the methylation profile in this etiologically distinct 
subclass of HCC reveals important epigenetic changes in virus-associated 
hepatocarcinogenesis.   
As an etiologically distinct subgroup of HCC, we speculate that perhaps HCV-
associated HCCs incur more epigenetic aberrations during carcinogenesis as a result of the 
burden of particularly high oxidative stress due to ROS overproduction. Apart from eliciting 
inflammation-mediated increases in cellular oxidative stress, one group has demonstrated 
that chronic HCV infection can increase levels of ROS independently of the inflammation 
response (10). Recently, Lim et al. (46) provided mechanistic evidence for the link between 
ROS production in HCV-infected liver and promoter hypermethylation after observing 
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increased promoter hypermethylation of the E-cadherin gene in human HCC cell lines 
following exposure to H2O2. Thus, it is reasonable to suggest that the high degree of 
promoter hypermethylation in both tumorous and non-tumorous tissues from HCV-
associated HCC patients can at least partially be accounted for by the overwhelming levels of 
HCV-induced oxidative stress. That ROS production and oxidative stress is such a 
paramount feature of HCV-associated hepatitis and HCV-associated cirrhosis pathogenesis, 
studies investigating the specific link between HCV infection and epigenetic alterations in 
precancerous pathologies are well-advised. 
In addition to demonstrating the existence of epigenetic aberrations in preneoplastic 
liver tissue, the high methylation frequencies observed in the surgical margin also provide 
epigenetic evidence for field cancerization in HCC and may be related to the rapidity of HCC 
recurrence following resection.  Field cancerization was initially described by Slaughter et al. 
(15) when they explained that recurrent oral tumors arise from histopathologically altered 
fields of preneoplastic lesions. But it is now more appropriately defined as the process by 
which either a second primary tumor (intrahepatic metastasis) or a second field tumor 
(polyclonally-derived) arises from the same pre-neoplastic lesion with genetically altered 
cells in a distinct, biological stage (16).  Previously, this model relied on the assumption that 
multiple liver tumors develop from a monoclonal origin (second primary tumor), an 
assumption that is controversial given the abundant evidence that HCCs can also include 
multicentric, polyclonal tumors (14).  To further explore the concept of field cancerization as 
it relates to epigenetic changes in HCV-associated HCC, we attempted to characterize the 
clonality of our HCC samples by determining the accordance between the tumorous and 
corresponding non-tumorous tissue pairs with regard to methylation status. For all of the 7 
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genes examined, the majority of cases were accordant for methylation status and only a small 
percentage (range, 0 to 15%) were discordant (e.g., unmethylated in the tumorous tissue, 
while methylated in non-tumorous tissue). However, when the methylation status of all genes 
is considered, 11 cases (28%) were discordant for at least one gene. This result largely 
supports a monoclonal theory of field cancerization in HCC, but also shows that, in a 
minority of cases, HCV-associated HCC tumors may also arise from multicentric origins, 
similar to what other investigators have found (29). 
A major focus of our study was to elucidate the relationship between changes in 
global or gene-specific DNA methylation and recurrence-free survival. The potential 
relevance of using methylation status as a predictor for overall or recurrence-free survival has 
been explored by several investigators with encouraging results. Hypermethylation of GSTP1 
and P16INK4A was significantly associated with reduced overall survival (22; 33), while 
MGMT hypermethylation in tumorous tissues and RIZ1 hypermethylation in non-tumorous 
tissues was significantly related to earlier recurrence (29).  Our study found that only 
methylation of RIZ1 in non-tumorous tissues was associated with an increased risk for earlier 
recurrence. This is consistent with the finding that RIZ1 promoter hypermethylation is an 
early event in hepatocarcinogenesis (45) and we posit that RIZ1 hypermethylation tested in 
biopsy specimens may serve as a pre-clinical marker of liver tumor development.  
Promoter hypermethylation of several cancer-related genes, including those tested 
herein, has been found to be inversely correlated with overall survival in HCC patients (25).   
However, when recurrence-free survival is used as an outcome, the relationship is less 
certain. Our study did not find that methylation status of the candidate genes, with the 
exception of RIZ1 in non-tumorous tissue, was predictive of tumor recurrence. This 
  36 
observation is similar to that reported by Lou et al. (29) and exposes the potential weakness 
of using gene methylation status for predicting the clinical outcomes in HCC. However, the 
fact that RIZ1 methylation in non-tumorous samples is predictive of recurrence-free survival 
in two independent cohorts (both one that is homogeneous with respect to HCV status, and a 
heterogeneous one (29)) maintains our optimistic outlook for prospective use of promoter 
hypermethylation as a potentially useful clinical biomarker.  
Though other investigators have found significant inverse correlations between the 
number of genes hypermethylated and patient survival, our study revealed no relationship 
between the number of genes methylated in either tumorous or non-tumorous sub-cohorts 
and reduced recurrence-free survival times. Promoter methylation status of the seven genes 
tested was unable to characterize post-resection prognoses in patients. We caution, however, 
that the number of genes examined in our study was limited and perhaps the addition of other 
candidate genes may yield better correlations between the number of methylated genes and 
recurrence-free survival.  Furthermore, because dozens of aberrantly methylated genes have 
been identified in HCC (e.g., 25), the selection of only seven genes for methylation analysis 
could have perhaps stochastically missed many other genes whose methylation status might 
have been related to recurrence-free survival. Importantly, however, the varying results 
between this study and others demonstrate how specific epigenetic changes in HCC may be 
representative of the distinct underlying etiology. 
 Several groups have recently demonstrated that global DNA hypomethylation often 
accompanies specific gene hypermethylation in HCC and contributes to carcinogenesis via 
protooncogene activation and overall genomic instability (25; 35; 44).  We also show that 
significant genomic hypomethylation, as assessed by LINE-1 methylation status, occurs 
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concomitantly with specific gene hypermethylation in tumorous tissues. Though we did not 
find a significant association between LINE-1 hypomethylation levels and recurrence-free 
survival using univariate Cox proportional hazards models, the level of hypomethylation in 
tumorous tissues from patients with earlier recurrences was significantly different than that in 
subjects with later recurrences, both when earlier recurrence was defined as <1 year and <2 
years. Hypomethylation in non-tumorous tissues did not differ after dichotomization 
according to recurrence time, in agreement with the study conducted by Calvisi et al. (25).   
It is noteworthy, however, when recurrence-free survival was assessed after dividing non-
tumorous tissues according to hypomethylation below and above the median level in non-
tumorous tissues, a high level of hypomethylation conferred an increased risk for earlier 
recurrence with modest significance. This finding suggests a role for global hypomethylation 
in promoting the development of additional tumors from non-neoplastic surrounding tissue 
and is one of a myriad of results from the present study that support the notion of pervasive 
epigenetic alterations in the liver remnant. As an epigenetic aberration, global changes in 
genomic methylation appears to occur independently of gene-specific promoter 
hypermethylation, as the two were neither correlated, nor was the level of hypomethylation 
associated with the number of genes methylated in a sample. 
 The theme that has emerged from the epigenetic investigations of the present study, 
then, is that perhaps epigenetic endpoints assessed in the precancerous liver remnant 
following tumor resection is as informative, if not more informative, than an investigation of 
epigenetic aberrations in tumorous tissues. Only the methylations status of RIZ1 in non-
tumorous tissue samples was significantly associated with recurrence-free survival. 
Additionally, the methylation status of RIZ1 and GSTP1 in non-tumorous tissues were 
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significantly associated with larger tumor diameter and more aggressive tumor stage, 
respectively, while methylation status for all of the genes in tumorous tissues were not 
related to the clinicopathological features most predictive of earlier recurrences (e.g., tumor 
diameter, tumor stage, and tumor number). And finally, hypomethylation levels in non-
tumorous tissues above the median value was nearly significantly associated with reduced 
recurrence-free survival. It is both biologically plausible and intuitive to recognize that 
epigenetic changes in precancerous lesions might be more useful clinical informants for 
identifying patients at-risk for developing earlier recurrences. Clinically detectable 
hepatocellular carcinomas represent a tissue type of extraordinary epigenetic and genetic 
aberrations. From the context of a myriad of molecular changes, tumors have progressed far 
beyond the non-tumorous counterpart from the surgical margin—tissue that appears 
histopathologically normal. Thus, epigenetic changes in non-tumorous tissue are inherently 
earlier events preceding a clinically detectable hepatocellular carcinoma, and it is perhaps not 
surprising epigenetic changes in the field—which will ultimately serve as the background 
from which additional tumors develop—are more associated with recurrence-free survival. 
We posit, then, that a careful investigation of the epigenetic and gene expression changes in 
the liver remnant can enhance the molecular information from tumorous tissues and other, 
more conventional clinicopathological features. 
 Our study has combined epigenetic analyses with whole genome microarray data. 
Because it is well-recognized that promoter hypermethylation may result in repression of the 
associated transcript, we aimed to characterize the relationship between methylation of 
specific genes and corresponding mRNA levels. We hypothesized that tissues in which gene 
promoters were methylated would also show decreased expression. Even though we found 
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significant differences in gene expression between tumorous and non-tumorous tissues for all 
of the genes but APC, the univariate Cox proportional hazard analyses showed that gene 
expression of these 7 genes was not associated with recurrence-free survival, with the 
exception of SOCS-1 expression in non-tumorous samples.  
RIZ1 and GSTP1 were the only genes whose expression was significantly lower in 
methylated samples when examining both tumorous and non-tumorous samples together. 
Counter-intuitively, expression of P16INK4A was actually significantly higher in samples 
showing P16INK4A methylation. When analyzed separately in the tumorous cohort, this 
relationship was upheld. Additionally, MGMT expression was significantly lower in 
methylated samples in the non-tumorous cohort. Though RIZ1 methylation was significantly 
associated with reduced recurrence-free survival and others have found a correlation between 
RIZ1 hypermethylation and reduced mRNA levels in tumorous tissues (47), our study did not 
confirm this. The lack of the expected correlation between promoter hypermethylation and 
gene expression in 5 of the 7 genes analyzed could be the result of examining only one CpG 
island per gene promoter, and not comprehensively analyzing methylation in the entire 
promoter region. Furthermore, promoter hypermethylation is just one biological modification 
affecting gene expression.  Because mRNA levels are quite dynamic, it is reasonable to 
hypothesize that other compensatory processes are operating as cells attempt to reverse 
changes in expression due to promoter hypermethylation.  In the dysregulated biological and 
molecular milieu of cancer, a host of mechanisms could be responsible for achieving this, 
including miRNA binding, chromatin and histone modifications, and larger chromosomal 
irregularities, such as loss of heterozygosity.  
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 To further investigate the apparent lack of a relationship between methylation status 
and gene expression, we adopted the converse approach, and selected genes for methylation 
analysis based on expression profiles of genes which were related to recurrence-free survival.  
Except for GATA-4, all of the nine genes identified with putative promoter CpG islands had 
not previously been reported in the literature, and thus were novel targets for analysis. 
However, none of these genes were methylated in 8 tumorous or 8 non-tumorous tissues 
following MSP analyses, including GATA-4, which was methylated in 58% of HCC cases in 
reports by others (25). Thus, overall, we conclude that there is lack of agreement between 
promoter methylation status and gene expression in a cohort of HCV-positive Japanese HCC 
patients, and we reason that assessment of methylation status alone is incapable of explaining 
the downstream cascade of events leading to dysregulated gene expression in HCV-
associated hepatocarcinogenesis. 
However, we must caution that the weak relationship demonstrated between promoter 
methylation status and downstream gene expression changes might also be accounted for by 
the tissue procurement procedure. The samples used in this study were not micro-dissected. 
Rather, they were whole tissue samples and thus represent a heterogeneous tissue with 
respect to the cellular sub-populations of cells (e.g., epithelium and the stroma). 
Consequently, overall observed gene expression changes can be regarded as the net 
contribution of gene expression changes in both the epithelial cells of the tumor and the 
supportive non-epithelial cells. It is conceivable that up-regulation of gene expression in 
stromal cells could have offset some of the decreases in gene expression due to promoter 
hypermethylation, as this could have occurred only in epithelial cells of the cancer. 
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 From a genome-wide perspective, then, it appears that gene expression signatures of 
recurrence-free survival are more difficult to characterize, because multiple other 
mechanisms that influence gene expression are likely operating, perhaps undetectably, and 
potentially in different cellular sub-populations. By focusing within a smaller, more gene-
specific context, however, patterns of methylation appear to be more stable and robust 
markers of the sequential accumulation of molecular aberrations along multistep 
hepatocarcinogenesis. Biomarkers such as RIZ1 hypermethylation in non-tumorous tissues 
may serve a more clinically useful role, as its association with earlier recurrence or as an 
early event in tumorigenesis is reproducible between studies (45; 47).  
 In summary, we examined some of the epigenetic changes incurred during HCV-
related hepatocarcinogenesis and demonstrate the technical and practical challenges of 
relating promoter methylation status to corresponding gene expression levels and recurrence-
free survival. Multiple genes in multiple pathways known to be improperly regulated during 
tumorigenesis were hypermethylated in both tumorous and non-tumorous tissues. 
Additionally, global changes in DNA hypomethylation were more pronounced in tumorous 
tissues. Together, our epigenetic data establishes an aberrant methylation profile in a cohort 
consisting of an etiologically distinct sub-group of HCV-positive HCC cases. The finding 
that RIZ1 methylation and increased levels of LINE-1 hypomethylation in non-tumorous 
tissues are associated with recurrence-free survival underscores the importance of assessing 
the epigenetic state of the liver remnant following tumor resection. 
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Study Limitations  
 
 Several features of this research project potentially limited the scope, applicability, 
and definitiveness of the aforementioned results. Perhaps the biggest limitation was the small 
sample size, which included only 43 tumorous tissues, 45 non-tumorous tissues, and 39 pairs 
from the same patient. Though the vast majority of literature on aberrant methylation in HCC 
uses patient cohorts that are less than 100 patients in size, one must acknowledge the low 
statistical power afforded by such a small sample size. In particular, dichotomizing cases by 
methylation status for most of the genes, both within the tumorous and non-tumorous sub-
cohorts, resulted in fewer than 10 cases in a group. The same limitation applies for the 
analyses of recurrence-free survival using Kaplan-Meier curves or Cox proportional hazards 
modeling. A larger sample size could have potentially increased the survival separation 
between methylated and unmethylated samples, uncovering more statistically significant 
relationships. However, procuring fresh-frozen tissue samples from HCC resection patients is 
always a difficult endeavor. 
 The small number of genes analyzed for methylation status (seven) also limited the 
scope of this study. Because there were clearly differences in the frequency of methylation 
according to different genes (e.g., 0% methylation of MGMT versus 100% methylation of 
RASSF1A in tumorous tissues), adding several more genes might have revealed a pattern of 
differential methylation according to the gene being analyzed (e.g., a group of genes with 
low, moderate, or high methylation frequencies in tumorous or non-tumorous tissues). 
 Methodologically, the MSP used in the analyses of gene-specific promoter 
methylation was inherently qualitative, in that it yielded dichotomous data (methylated or not 
methylated). Real-time, quantitative MSP has only recently become a reliable method for 
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investigating methylation in cancer, and thus simple MSP is still frequently used in 
epigenetic studies of HCC. However, the use of quantitative MSP could expose differences 
in methylation according to tissue type, recurrence-free survival, or other clinicopathological 
variables that are perhaps indiscernible with simple MSP. 
 
Further Avenues of Research 
 
 Future directions of research generated from the present project would include the 
addition of at least 20 more genes for MSP analysis. To investigate the relationship between 
HCV-associated ROS production and HCC (9), several of these genes would be related to 
mechanisms of ROS scavenging and/or DNA adduct repair. A quantitative, real-time MSP 
assay would replace the simple qualitative one. This technique would generate far more 
quantitative data, however, and one would probably need to enlist the services of expert 
bioinformaticists/biostatisticians. Recognizing that normal aging livers can exhibit detectable 
levels of DNA methylation through this technique (32), this improvement would require age-
matched control DNA to allow meaningful comparisons between levels of methylation and to 
ensure conclusions regarding the methylation status was due to pathology and not simply an 
artifact of natural aging. Hierarchical clustering of the level of gene-specific methylation 
could potentially produce easily identifiable patterns in methylation levels according to the 
tissue type or other pre-selected variables, and pathway analyses of the implicated genes 
could be performed.  
The addition of tissues obtained from HCV-positive, HBV-negative cirrhotic livers 
would allow the assessment of the sequential epigenetic changes as the liver pathology 
progresses from normal (but aging) to cirrhotic, to the non-neoplastic margin, to HCC, and 
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would permit more explicit characterization of the epigenetic alterations accompanying 
HCV-associated HCC.  
To bolster data obtained from MSP analyses, this project could expand to include 
immunohistochemistry experiments to test for the protein products of the cancer-related 
genes. If the functional consequence of promoter hypermethylation is reduced gene 
expression, and hence, reduced protein product, then the demonstration of correspondingly 
less protein in methylated tissues could validate the results of the methylation status. 
Lastly, because promoter hypermethylation is just one epigenetic mechanism 
involved in hepatocarcinogenesis, this project would be enhanced by an investigation into 
other epigenetic changes that might be associated with recurrence-free survival, such as 
determining histone acetylation status using chromatin immunoprecipitation assays.  
 
Concluding Remarks 
 
 That carcinogenesis is a complex, multistep process of both epigenetic and genetic 
aberrations has been recognized for decades.  This study provides results that seem to add an 
additional layer of intricacy to the molecular enigma of hepatocarcinogenesis. It is manifest 
both from the high frequencies of gene methylation in non-tumorous tissues and from the 
numerous relationships found between epigenetic changes in non-tumorous tissues, 
clinicopathological variables, and recurrence-free survival that preneoplastic tissue from the 
surrounding margin is severely compromised in HCV-positive HCC patients.  Because HCC 
tumor recurrence in patients undergoing curative resection surgery is particularly rapid and 
unavoidable, the field of hepatocarcinogenesis research must continue to focus on identifying 
and characterizing biomarkers of liver pathology that offer prospective utility.  The capacity 
to detect aberrant promoter methylation in serum DNA several years before clinical detection 
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of HCC, and the power of this methylation status for predicting HCC (37) inspires hope in 
the quest for earlier HCC detection, earlier treatment, and longer survival in patients afflicted 
by this devastating cancer. 
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